IN8bio, Inc. INAB
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -60.41%
- 1 year
- -44.19%
- Market cap
- 9.13M
- EPS (ttm)
- -1.62
- Shares out
- 72.48M
- Forward P/E
- -0.80
- YTD return
- -60.41%
- 1-year return
- -44.19%
- Volume
- 33.38K
- Avg volume
- 50.88K
- Open
- 0.9685
- Previous close
- 0.83
- Day's range
- 0.88 – 1.00
- 52-week range
- 0.80 – 2.73
- Beta
- -0.07
- Analysts
- Buy
- Price target
- 4.75 (+412.7%)
- Earnings date
- Aug 8, 2024
2Y -9.0935 (-90.75%)
Key statistics
- Enterprise value
- 12.05M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.41M
- Total cash
- 10.22M
- Total debt
- 5.90M
- Return on equity
- -180.45%
- Short % of float
- 1.83%
- 50-day average
- 0.3045
- 200-day average
- 0.70842
Analyst view
Consensus: buy
- Target (low)
- 1.50
- Target (mean)
- 4.75
- Target (high)
- 8.00
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.08.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.14 | -0.15 | -0.01 | -7.14% |
| Aug 8, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.16 | -0.19 | -0.03 | -18.75% |
| May 9, 2024 | Mar 1, 2024 | -0.17 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.17 | -0.20 | -0.03 | -17.65% |
| Mar 14, 2024 | Dec 1, 2023 | -0.16 | -0.21 | -0.05 | -31.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2024 | Jones Trading | down | Buy | Hold |
| Jun 14, 2024 | Jones Trading | main | Buy | Buy |
| Jun 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- in8bio.com
News
12 Health Care Stocks Moving In Thursday's After-Market Session 
IN8bio Q2 EPS $(0.25) Beats $(0.37) Estimate 
12 Health Care Stocks Moving In Thursday's After-Market Session 
IN8bio Announces Publication Of Peer-Reviewed Clinical Data From Phase 1 Trial Of INB-200 In The Journal Of Clinical Oncology 
12 Health Care Stocks Moving In Thursday's After-Market Session - IN8bio Publishes Nature Communications Review Highlighting Engineered γδ T Cell Cancer Therapies And Combination Treatment Advances
IN8bio Presents New Translational Data Of Its DeltEx DRI Platform At ISCT 2026 Annual Meeting And ASGCT 2026 Annual Meeting 
IN8bio Q1 EPS $(0.26) Beats $(0.69) Estimate 
HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $6 Price Target 
IN8bio Promotes Kate Rochlin To President, COO, Effective Immediately
Your note
Sign in to keep a note on INAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRANDT PETER C | Director | Stock Award(Grant) | Oct 3, 2024 | 622,894 |
| EPPERLY CORINNE | Director | Stock Award(Grant) | Dec 12, 2023 | 81,967 |
| GOSWAMI TRISHNA | Officer | Stock Award(Grant) | Dec 12, 2023 | 6,729 |
| GRAFF JEREMY R. | Director | Stock Award(Grant) | Dec 12, 2023 | 4,549 |
| HO WILLIAM TAI WEI | Chief Executive Officer | Stock Award(Grant) | Oct 3, 2024 | 2,803,590 |
| LAMB LAWRENCE S. | Officer | Stock Award(Grant) | Dec 12, 2023 | 101,369 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 2.31% | 1,674,638 | 401.91K | Sep 29, 2024 |
| Vanguard Group Inc | 1.96% | 1,423,897 | 341.74K | Sep 29, 2024 |
| 683 Capital Management LLC | 1.86% | 1,350,304 | 324.07K | Sep 29, 2024 |
| Sigma Planning Corp | 1.17% | 851,280 | 204.31K | Sep 29, 2024 |
| Ensign Peak Advisors, Inc | 1.14% | 829,176 | 199.00K | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 0.60% | 434,809 | 104.35K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.31% | 952,487 | 228.60K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.65% | 471,410 | 113.14K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.24% | 173,058 | 41.53K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 61,228 | 14.69K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.07% | 51,554 | 12.37K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 36,345 | 8.72K | Oct 30, 2024 |